Interleukin-2

"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.

Descriptor ID	D007376
MeSH Number(s)	D12.644.276.374.465.021 D12.644.276.374.480.372 D12.776.467.374.465.021 D12.776.467.374.480.372 D23.529.374.465.155 D23.529.374.480.372
Concept/Terms	Interleukin-2 Interleukin-2 Interleukin 2 IL-2 IL2 TCGF Interleukine 2 Lymphocyte Mitogenic Factor Mitogenic Factor, Lymphocyte T-Cell Growth Factor T Cell Growth Factor T-Cell Stimulating Factor T Cell Stimulating Factor Thymocyte Stimulating Factor Interleukin II Ro-23-6019 Ro-23-6019 Ro 23 6019 Ro236019 Ro-236019 Ro 236019 RU 49637 RU 49637 RU-49637 RU49637

Below are MeSH descriptors whose meaning is more general than "Interleukin-2".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Cytokines [D12.644.276.374]
Interleukins [D12.644.276.374.465]
Interleukin-2 [D12.644.276.374.465.021]
Lymphokines [D12.644.276.374.480]
Interleukin-2 [D12.644.276.374.480.372]
Proteins [D12.776]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Cytokines [D12.776.467.374]
Interleukins [D12.776.467.374.465]
Interleukin-2 [D12.776.467.374.465.021]
Lymphokines [D12.776.467.374.480]
Interleukin-2 [D12.776.467.374.480.372]
Biological Factors [D23]
Intercellular Signaling Peptides and Proteins [D23.529]
Cytokines [D23.529.374]
Interleukins [D23.529.374.465]
Interleukin-2 [D23.529.374.465.155]
Lymphokines [D23.529.374.480]
Interleukin-2 [D23.529.374.480.372]

Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.

Bar chart showing 42 publications over 14 distinct years, with a maximum of 6 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	2	0	2
1994	1	0	1
1995	1	1	2
1997	0	1	1
1998	1	1	2
2002	3	3	6
2003	1	2	3
2004	2	2	4
2005	3	2	5
2006	1	3	4
2007	3	1	4
2008	4	0	4
2009	1	1	2
2010	0	2	2

Below are the most recent publications written about "Interleukin-2" by people in Profiles.

Loza MJ, Foster S, Bleecker ER, Peters SP, Penn RB. Asthma and gender impact accumulation of T cell subtypes. Respir Res. 2010; 11:103.

View in: PubMed
El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther. 2010 Jan; 9(1):57-66.

View in: PubMed
Phillips SM, Bhopale MK, Hilliard B, Zekavat SA, Ali MA, Rostami A. Suppression of murine experimental autoimmune encephalomyelitis by interleukin-2 receptor targeted fusion toxin, DAB(389)IL-2. Cell Immunol. 2010; 261(2):144-52.

View in: PubMed
Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol Cancer. 2009; 8:67.

View in: PubMed
Benson DM, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 2009 Mar 19; 113(12):2706-14.

View in: PubMed
Snook AE, Huang L, Schulz S, Eisenlohr LC, Waldman SA. Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens. Clin Transl Sci. 2008 Dec; 1(3):263-4.

View in: PubMed
Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother. 2008 Jul-Aug; 31(6):569-76.

View in: PubMed
Plesa G, Snook AE, Waldman SA, Eisenlohr LC. Derivation and fluidity of acutely induced dysfunctional CD8+ T cells. J Immunol. 2008 Apr 15; 180(8):5300-8.

View in: PubMed
Loza MJ, Foster S, Peters SP, Penn RB. Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells. J Allergy Clin Immunol. 2008 Mar; 121(3):750.e1-5.e3.

View in: PubMed
Phillips SM, Bhopale MK, Constantinescu CS, Ciric B, Hilliard B, Ventura E, Lavi E, Rostami A. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. J Neurol Sci. 2007 Dec 15; 263(1-2):59-69.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement